Author:
Mehnert Janice M.,Varga Andrea,Brose Marcia S.,Aggarwal Rahul R.,Lin Chia-Chi,Prawira Amy,de Braud Filippo,Tamura Kenji,Doi Toshihiko,Piha-Paul Sarina A.,Gilbert Jill,Saraf Sanatan,Thanigaimani Pradeep,Cheng Jonathan D.,Keam Bhumsuk
Funder
Merck & Co., Inc., Kenilworth, NJ, USA
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference23 articles.
1. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii110–9.
2. National Cancer Institute: SEER Stat Fact Sheets: Thyroid Cancer. In.; 2016.
3. Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016;7(22):32318–28.
4. National Comprehensive Cancer Network I: NCCN clinical practice guidelines in oncology - thyroid carcinoma v1.2016. In. Edited by 1.2016; 2016.
5. Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30–40.
Cited by
144 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献